MX2012003759A - Metodos y composiciones para tratamiento de fibrosis ocular. - Google Patents
Metodos y composiciones para tratamiento de fibrosis ocular.Info
- Publication number
- MX2012003759A MX2012003759A MX2012003759A MX2012003759A MX2012003759A MX 2012003759 A MX2012003759 A MX 2012003759A MX 2012003759 A MX2012003759 A MX 2012003759A MX 2012003759 A MX2012003759 A MX 2012003759A MX 2012003759 A MX2012003759 A MX 2012003759A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treatment
- compositions
- ocular fibrosis
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se dan a conocer en este documento métodos y composiciones para el tratamiento de fibrosis ocular, como ocurre por ejemplo durante el tratamiento de glaucoma mediante trabeculectomía. Las composiciones comprenden moduladores de la actividad de una o más enzimas de tipo lisil oxidasa (por ejemplo, LOX, LOXL2), y los métodos incluyen métodos para hacer los moduladores y métodos para la administración de los moduladores a un sujeto en necesidad de la misma.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27791809P | 2009-09-29 | 2009-09-29 | |
US39745610P | 2010-06-11 | 2010-06-11 | |
PCT/US2010/050542 WO2011041309A1 (en) | 2009-09-29 | 2010-09-28 | Methods and compositions for treatment of ocular fibrosis |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012003759A true MX2012003759A (es) | 2012-07-23 |
Family
ID=43780639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012003759A MX2012003759A (es) | 2009-09-29 | 2010-09-28 | Metodos y composiciones para tratamiento de fibrosis ocular. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110076285A1 (es) |
EP (1) | EP2482814A4 (es) |
JP (1) | JP2013506005A (es) |
KR (1) | KR20120091146A (es) |
CN (1) | CN102711753A (es) |
AU (1) | AU2010300813A1 (es) |
BR (1) | BR112012007114A2 (es) |
CA (1) | CA2775877A1 (es) |
MX (1) | MX2012003759A (es) |
RU (1) | RU2012117896A (es) |
WO (1) | WO2011041309A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
ES2534490T3 (es) * | 2007-08-02 | 2015-04-23 | Gilead Biologics, Inc. | Inhibidores de LOX y LOXL2 y usos de los mismos |
US9107935B2 (en) * | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
EP2393923A4 (en) * | 2009-02-06 | 2012-11-14 | Gilead Biologics Inc | METHOD AND COMPOSITIONS FOR TREATING NEOVASCULARIZATION |
US20110044907A1 (en) * | 2009-08-21 | 2011-02-24 | Derek Marshall | In vivo screening assays |
CA2771786A1 (en) * | 2009-08-21 | 2011-02-24 | Gilead Biologics, Inc. | In vivo screening assays |
US20110076272A1 (en) * | 2009-08-21 | 2011-03-31 | Victoria Smith | Therapeutic methods and compositions |
CN102712683B (zh) | 2009-08-21 | 2014-09-10 | 吉联亚生物科技有限公司 | 赖氨酰氧化酶和loxl2的催化结构域 |
CN103370080A (zh) * | 2010-02-04 | 2013-10-23 | 吉联亚生物科技有限公司 | 结合赖氨酰氧化酶样2(loxl2)的抗体和其使用方法 |
ES2959242T3 (es) | 2016-03-08 | 2024-02-22 | Univ Utah Res Found | Agentes de reticulación y métodos asociados |
WO2018035441A1 (en) * | 2016-08-19 | 2018-02-22 | Colorado State University Research Foundation | Methods and compositions for treating equine conditions using recombinant self-complementary adeno-associated virus |
CA3073137A1 (en) | 2016-08-19 | 2018-02-22 | Jeffrey S. Bartlett | Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus |
KR20190088561A (ko) | 2016-12-07 | 2019-07-26 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 인터류킨-1 수용체 길항제(IL-1RA) cDNA |
WO2019178329A1 (en) * | 2018-03-16 | 2019-09-19 | The Regents Of The University Of Michigan | Compositions and methods for treating graves disease |
GB201809295D0 (en) | 2018-06-06 | 2018-07-25 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
KR20200030875A (ko) | 2018-09-13 | 2020-03-23 | 전남대학교산학협력단 | 트리코스타틴 a를 유효성분으로 포함하는 결막 섬유화 억제용 약학적 조성물 |
GB201818750D0 (en) | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
GB202209622D0 (en) | 2022-06-30 | 2022-08-17 | Institute Of Cancer Res Royal Cancer Hospital | Compounds |
GB202209624D0 (en) | 2022-06-30 | 2022-08-17 | Institute Of Cancer Res Royal Cancer Hospital | Prodrugs |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6300092B1 (en) * | 1999-01-27 | 2001-10-09 | Millennium Pharmaceuticals Inc. | Methods of use of a novel lysyl oxidase-related protein |
US20030152926A1 (en) * | 1999-08-11 | 2003-08-14 | Eos Biotechnology, Inc. | Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
US20030114410A1 (en) * | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
US20060134172A1 (en) * | 2004-12-21 | 2006-06-22 | Alcon, Inc. | Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
US20070225242A1 (en) * | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
US20070021365A1 (en) * | 2005-06-21 | 2007-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto |
IL184627A0 (en) * | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
ES2534490T3 (es) * | 2007-08-02 | 2015-04-23 | Gilead Biologics, Inc. | Inhibidores de LOX y LOXL2 y usos de los mismos |
US8815946B2 (en) * | 2008-01-25 | 2014-08-26 | University of Pittsburgh—of the Commonwealth System of Higher Education | Inhibition of proliferation and fibrotic response of activated corneal stromal cells |
US9107935B2 (en) * | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
EP2393923A4 (en) * | 2009-02-06 | 2012-11-14 | Gilead Biologics Inc | METHOD AND COMPOSITIONS FOR TREATING NEOVASCULARIZATION |
US20110044907A1 (en) * | 2009-08-21 | 2011-02-24 | Derek Marshall | In vivo screening assays |
CA2771786A1 (en) * | 2009-08-21 | 2011-02-24 | Gilead Biologics, Inc. | In vivo screening assays |
CN102712683B (zh) * | 2009-08-21 | 2014-09-10 | 吉联亚生物科技有限公司 | 赖氨酰氧化酶和loxl2的催化结构域 |
US20110076272A1 (en) * | 2009-08-21 | 2011-03-31 | Victoria Smith | Therapeutic methods and compositions |
-
2010
- 2010-09-28 KR KR1020127010920A patent/KR20120091146A/ko not_active Application Discontinuation
- 2010-09-28 AU AU2010300813A patent/AU2010300813A1/en not_active Abandoned
- 2010-09-28 WO PCT/US2010/050542 patent/WO2011041309A1/en active Application Filing
- 2010-09-28 BR BR112012007114A patent/BR112012007114A2/pt not_active IP Right Cessation
- 2010-09-28 US US12/892,574 patent/US20110076285A1/en not_active Abandoned
- 2010-09-28 EP EP10821110A patent/EP2482814A4/en not_active Withdrawn
- 2010-09-28 JP JP2012532238A patent/JP2013506005A/ja not_active Withdrawn
- 2010-09-28 MX MX2012003759A patent/MX2012003759A/es not_active Application Discontinuation
- 2010-09-28 RU RU2012117896/15A patent/RU2012117896A/ru not_active Application Discontinuation
- 2010-09-28 CA CA2775877A patent/CA2775877A1/en not_active Abandoned
- 2010-09-28 CN CN2010800538989A patent/CN102711753A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20120091146A (ko) | 2012-08-17 |
BR112012007114A2 (pt) | 2016-07-05 |
EP2482814A1 (en) | 2012-08-08 |
WO2011041309A1 (en) | 2011-04-07 |
CA2775877A1 (en) | 2011-04-07 |
CN102711753A (zh) | 2012-10-03 |
US20110076285A1 (en) | 2011-03-31 |
RU2012117896A (ru) | 2013-11-10 |
EP2482814A4 (en) | 2013-04-03 |
AU2010300813A1 (en) | 2012-04-26 |
JP2013506005A (ja) | 2013-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012003759A (es) | Metodos y composiciones para tratamiento de fibrosis ocular. | |
MX2011008296A (es) | Metodos y composiciones para el tratamiento de neovascularizacion. | |
WO2010127152A3 (en) | Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors | |
WO2008076556A3 (en) | Generation of inner ear cells | |
WO2008085221A3 (en) | Therapeutic use of cd31 expressing cells | |
WO2009115557A3 (en) | Fungicide hydroximoyl-tetrazole derivatives | |
MX2007008790A (es) | Pirazolo piridinas sustituidas, composiciones que las contienen, metodo de produccion de las mismas, y su uso. | |
WO2010080769A3 (en) | Chemotherapeutic methods and compositions | |
WO2009098698A3 (en) | Compartmental extract compositions for tissue engineering | |
MX2010005889A (es) | Derivados de tiofeno como agonistas de s1p1/edg1. | |
MX2012006881A (es) | Composiciones de povidona-yodo oftalmicas no irritantes. | |
MY147949A (en) | Hydrogenated benzo[c]thiophene derivatives as immunomodulators | |
MX2010007677A (es) | Derivados de hidroximoil-tetrazol como fungicidas. | |
EA201170703A1 (ru) | Производные адамантилбензамида | |
WO2009024677A3 (fr) | Utilisation d ' acide hyaluronique pour la preparation de compositions destinees a l' amelioration de la fonction de protection de la peau, de l' oeil et des muqueuses | |
WO2011087548A3 (en) | Therapeutic compositions and methods for targeted delivery of active agents | |
GB0806746D0 (en) | Membrane | |
MY159035A (en) | Control agent for soft rot and control method for the same | |
CA2770066C (en) | Prostacyclin, analogue or derivative thereof for the treatment of cystic fibrosis | |
MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
TW200942524A (en) | Novel aminomethyl benzene derivatives | |
MX2010000266A (es) | Un método para disminuir los síntomas del consumo de alcohol. | |
WO2010062762A3 (en) | Compositions and methods for reducing the signs of aging of the skin | |
WO2010147830A3 (en) | Aminothiazole modulators of beta-3-adrenoreceptor | |
MX2012012941A (es) | Nuevas composiciones oftalmicas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |